1
|
Caroleo B, Caroleo MC, Cimellaro A, Colangelo L, Perticone M, Di Mizio G, De Sarro G, Gallelli L. Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. Curr Drug Saf 2019; 14:67-71. [PMID: 30444202 DOI: 10.2174/1574886313666181116100452] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 10/25/2018] [Accepted: 11/12/2018] [Indexed: 12/26/2022]
Abstract
BACKGROUND Direct-acting Antivirals (DAA) are currently used in the treatment of chronic HCV infection. In patients with renal failure Glecaprevir/Pibrentasvir (genotype 1-6) is recommended for its safety and efficacy. CASE PRESENTATION Although these pharmacological characteristics, an adverse drug reaction (ADR) has been reported during Glecaprevir/Pibrentasvir treatment, such as the development of cholestatic jaundice in an elderly patient with chronic HCV (genotype 2) infection. At examination, patient was jaundiced associated with intense pruritus. RESULTS Ultrasound and laboratory biochemical tests excluded a liver failure (e.g. liver cancer, and liver lithiasis) or pancreatic cancer while Naranjo probability scale (score 6) suggested an association between cholestatic jaundice and Glecaprevir/Pibrentasvir administration. About 1 month after drug discontinuation, an improvement has been documented in both jaundice and pruritus, with a normalization in bilirubin levels (total bilirubin: 0.96 mg/dL), HCV-RNA was undetected also. It is worth mentioning that although we reported the development of cholestatic jaundice upon treatment with Glecaprevir/Pibrentasvir we recorded a clinical efficacy (HCV-RNA <15 IU/L) after 4 weeks from the beginning of the treatment, with a complete remission of clinical symptoms until 7 months after drug discontinuation. CONCLUSION These data support the clinical efficacy of Glecaprevir/Pibrentasvir association in elderly patients, despite the sub-optimal period of treatment.
Collapse
Affiliation(s)
- Benedetto Caroleo
- Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| | - Maria Cristina Caroleo
- Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende (CS), Calabria, Italy
| | - Antonio Cimellaro
- Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| | - Lidia Colangelo
- Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| | - Maria Perticone
- Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| | - Giulio Di Mizio
- Department of Law and Economic Science, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Sciences, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| | - Luca Gallelli
- Department of Health Sciences, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy
| |
Collapse
|
2
|
Colosimo M, Grancini A, Daprai L, Giovanni Cimminiello A, Castelli C, Restelli A, Gallelli L, Torresani E. Involvement of Campylobacter jejuni in septic arthritis: a case report. JMM Case Rep 2015. [DOI: 10.1099/jmmcr.0.000095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Manuela Colosimo
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Anna Grancini
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Laura Daprai
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Aldo Giovanni Cimminiello
- Emergency Medicine Unit, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Cristina Castelli
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Antonella Restelli
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| | - Luca Gallelli
- Department of Health Science, Operative Unit of Clinical Pharmacology and Pharmacovigilance, University of Catanzaro, Catanzaro, Italy
| | - Erminio Torresani
- Central Laboratory, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
| |
Collapse
|
3
|
Yin Z, Ma L, Xu J, Xia J, Luo D. Pustular drug eruption due to Panax notoginseng saponins. DRUG DESIGN DEVELOPMENT AND THERAPY 2014; 8:957-61. [PMID: 25114505 PMCID: PMC4109629 DOI: 10.2147/dddt.s67015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Panax notoginseng saponins (PNS) are a patented product in the People’s Republic of China, and have extensive effects on the cardiovascular system. Here we report on four elderly patients (one male and three female) with drug eruption induced by PNS injection. All developed a sudden skin rash with pruritus from head to foot, and subsequently accepted hospitalization. In each case, PNS had been used for less than 1 week before appearance of the rash. No specific short-term medications or changes in diet or exposure to environmental factors immediately prior to appearance of the rash were identified. These four patients had some interesting features in common, ie, pustules, fever, and elevated circulating neutrophil counts, which required high-dose, long-term glucocorticoid therapy. To our knowledge, this is the first report of pustular drug eruption induced by PNS and provides a useful reference and warning for clinicians.
Collapse
Affiliation(s)
- ZhiQiang Yin
- Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, People's Republic of China
| | - LiWen Ma
- Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, People's Republic of China
| | - JiaLi Xu
- Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, People's Republic of China
| | - JiPing Xia
- Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, People's Republic of China
| | - Dan Luo
- Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, People's Republic of China
| |
Collapse
|
4
|
De Vuono A, Palleria C, Scicchitano F, Squillace A, De Sarro G, Gallelli L. Skin rash during treatment with generic itraconazole. J Pharmacol Pharmacother 2014; 5:158-60. [PMID: 24799820 PMCID: PMC4008915 DOI: 10.4103/0976-500x.130086] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Revised: 06/04/2013] [Accepted: 07/12/2013] [Indexed: 11/16/2022] Open
Abstract
Generic drugs have the same active substance, the same pharmaceutical form, the same therapeutic indications and a similar bioequivalence with the reference medicinal product (branded). Although a similar efficacy is postulated, some cases of clinical inefficacy during treatment with generic formulations have been reported. In this case, we describe a woman with onychomycosis that developed a skin rash during treatment with a generic formulation of itraconazole. Drug administration and its re-challenge confirmed the association between itraconazole and skin rash. Both Naranjo probability scale and World Health Organization causality assessment scale documented a probable association between generic-itraconazole and skin rash. The switch from generic formulation to brand one induced an improvement of symptoms. Since we are unable to evaluate the role of each excipient in the development of skin rash, we cannot rule out their involvement. However, more data are necessary to better define the similarities or differences between branded and generic formulations.
Collapse
Affiliation(s)
- Antonio De Vuono
- Department of General Medicine, Cosenza, University of Catanzaro, Italy ; Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy
| | - Caterina Palleria
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy ; Department of Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | - Francesca Scicchitano
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy ; Department of Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | - Aida Squillace
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy ; Department of Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy ; Department of Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | - Luca Gallelli
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy ; Department of Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| |
Collapse
|
5
|
Dermatologic Side Effects of Psychotropic Medications. PSYCHOSOMATICS 2014; 55:1-20. [DOI: 10.1016/j.psym.2013.07.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2013] [Revised: 07/09/2013] [Accepted: 07/10/2013] [Indexed: 12/21/2022]
|
6
|
Gallelli L, Palleria C, De Vuono A, Mumoli L, Vasapollo P, Piro B, Russo E. Safety and efficacy of generic drugs with respect to brand formulation. J Pharmacol Pharmacother 2013; 4:S110-4. [PMID: 24347975 PMCID: PMC3853662 DOI: 10.4103/0976-500x.120972] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Generic drugs are equivalent to the brand formulation if they have the same active substance, the same pharmaceutical form and the same therapeutic indications and a similar bioequivalence respect to the reference medicinal product. The use of generic drugs is indicated from many countries in order to reduce medication price. However some points, such as bioequivalence and the role of excipients, may be clarified regarding the clinical efficacy and safety during the switch from brand to generic formulations. In conclusion, the use of generic drugs could be related with an increased days of disease (time to relapse) or might lead to a therapeutic failure; on the other hand, a higher drug concentration might expose patients to an increased risk of dose-dependent side-effects.
Collapse
Affiliation(s)
- Luca Gallelli
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy and Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | - Caterina Palleria
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy and Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | | | - Laura Mumoli
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy and Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| | | | | | - Emilio Russo
- Department of Health Science, Regional Center on drug information, Mater Domini University Hospital, Italy and Chair of Pharmacology, School of Medicine, University of Catanzaro, Italy
| |
Collapse
|
7
|
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci 2013; 2013:313858. [PMID: 23737767 PMCID: PMC3667469 DOI: 10.1155/2013/313858] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2013] [Revised: 04/09/2013] [Accepted: 04/16/2013] [Indexed: 12/26/2022] Open
Abstract
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure.
Collapse
|
8
|
Onishi A, Yamamoto H, Akimoto T, Saito O, Inoue M, Ando Y, Muto S, Kusano E. Reversible acute renal failure associated with clomipramine-induced interstitial nephritis. Clin Exp Nephrol 2007; 11:241-243. [PMID: 17891354 DOI: 10.1007/s10157-007-0485-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Accepted: 06/11/2007] [Indexed: 11/25/2022]
Abstract
We describe a 41-year old man with obsessive-compulsive neurosis who developed acute renal failure (ARF) due to acute interstitial nephritis (AIN) during 6 weeks of treatment with clomipramine hydrochloride (CPH). He had a slight fever, mild arthralgia, appetite loss, and diarrhea after taking CPH. On admission, he showed serum creatinine (sCr) of 7.31 mg/dl, and creatinine clearance (Ccr) of 2.5 ml/min. He subsequently became anuric and required hemodialysis. Renal biopsy revealed AIN with diffuse mononuclear cell infiltration. After the withdrawal of CPH and treatment with prednisolone (PSL) 0.5 mg/kg per day, his urinary output improved, along with improvement of his renal function; therefore hemodialysis was finally discontinued. To our knowledge, this is the first case report of AIN induced by clomipramine.
Collapse
Affiliation(s)
- Akira Onishi
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Hisashi Yamamoto
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Tetsu Akimoto
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan.
| | - Osamu Saito
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Makoto Inoue
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Yasuhiro Ando
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Shigeaki Muto
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| | - Eiji Kusano
- Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan
| |
Collapse
|
9
|
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2007. [DOI: 10.1002/pds.1368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|